Salus Hosts CITT-ART Full Investigator Meeting

Salus University recently hosted the Convergence Insufficiency Treatment Trial - Attention and Reading Trial (CITT-ART) Full Investigator Meeting on Monday, June 27. The five-year, eight million dollar study funded by The National Eye Institute will run through 2019. In addition to Salus, other sites involved in the study include: Bascom Palmer Eye Institute, Children’s Hospital of Akron, Ohio State University, NOVA, SCCO, SUNY, the Advanced Vision Center in Schaumberg, IL, and the University of Alabama.  

This randomized, placebo-controlled study is designed to investigate whether vision therapy for Convergence Insufficiency (CI) improves reading abilities and attention in children nine to 14 years old. The objectives of the study are to compare the effectiveness of office-based vision therapy and office-based placebo therapy for the treatment of CI, develop more precise estimates of success rates of treatment, and identify specific aspects associated with successful treatment. In the first two years, 204 children have been recruited and approximately 324 children will take part in the study.

The Full Investigator Meeting, led by Dr. Mitchell Scheiman, dean of Research at Salus University and the CITT-ART National Study Chair, reviewed the study design and protocol changes that occurred during the first two years of the study. The major role of a full investigator meeting is to certify new investigators, re-certify current investigators, and to build team spirit. Dr. Michael Gallaway, associate professor at Salus University Pennsylvania College of Optometry, is the University’s principal investigator for the study.

If you know a child in the nine to 14 year old age range with convergence insufficiency, suggest they consider enrolling in the CITT-ART study. 

More information on CITT-ART